DelveInsight’s “IgA Nephropathy Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the IgA Nephropathy, historical and forecasted epidemiology as well as the IgA Nephropathy market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The latest healthcare forecast report provides an in-depth analysis of IgA Nephropathy, offering comprehensive insights into the IgA Nephropathy revenue trends, prevalence, and treatment landscape. The report delves into key IgA Nephropathy statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging IgA Nephropathy therapies. Additionally, we cover the landscape of IgA Nephropathy clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of IgA Nephropathy treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the IgA Nephropathy space.
To Know in detail about the IgA Nephropathy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; IgA Nephropathy Market Forecast
Some of the key facts of the IgA Nephropathy Market Report:
-
The IgA Nephropathy market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
-
Key IgA Nephropathy Companies: Novartis, Vera Therapeutics, RemeGen Co., Ltd., Anthera Pharmaceuticals, Chinook Therapeutics, Inc., Rigel Pharmaceuticals, Calliditas Therapeutics AB, Hoffmann-La Roche, Ionis Pharmaceuticals, Keymed Biosciences, and others
-
Key IgA Nephropathy Therapies: Iptacopan (LNP023), Atacicept, Atrasentan, RC18, Telitacicept, Blisibimod, BION-1301, Fostamatinib, NEFECON, RO7434656, IONIS-FB-LRx, Tacrolimus, and others
-
The IgA Nephropathy market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage IgA Nephropathy pipeline products will significantly revolutionize the IgA Nephropathy market dynamics.
-
In 2023, the diagnosed prevalent cases of IgA nephropathy (IgAN) across the 7MM were approximately 395,500.
-
Among the 7MM, Japan had the largest share of diagnosed prevalent cases of IgA nephropathy (IgAN), representing approximately 45% of the total population.
-
According to the analysis, IgA nephropathy exhibits a male predominance, with approximately 62,600 cases in males and around 46,900 cases in females in the US in 2023.
-
In 2023, in the US, it was estimated that approximately 8,800 cases of IgA nephropathy were in the 0-18 age group. The prevalence increased with age, peaking in the 19-44 age group with about 45,000 cases. However, the incidence decreased in individuals over 45 years old.
-
In April 2024, European Commission (EC) granted conditional marketing authorization (CMA) to FILSPARI for the treatment of adults with primary IgAN with a urine protein excretion ≥1.0 g/day (or urine protein-to-creatinine ratio ≥0.75 g/g).
-
In December 2023, Calliditas Therapeutics announced full FDA approval of TARPEYO delayed release capsules to reduce the loss of kidney function in adults with primary IgAN.
IgA Nephropathy Overview
IgA nephropathy, also known as Berger’s disease, is a kidney disorder characterized by the buildup of immunoglobulin A (IgA) in the glomeruli, the filtering units of the kidneys. This condition is one of the most common causes of glomerulonephritis, which is inflammation of the glomeruli. The progression of IgA nephropathy varies. Some individuals may experience a slow progression with few symptoms, while others may develop chronic kidney disease or end-stage renal disease (ESRD) over time.
Get a Free sample for the IgA Nephropathy Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/iga-nephropathy-igan-market
IgA Nephropathy Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
IgA Nephropathy Epidemiology Segmentation:
The IgA Nephropathy market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
-
Total Diagnosed Prevalent Cases of IgA Nephropathy in the 7MM
-
Gender-specific Cases of IgA Nephropathy in the 7MM
-
Age-specific Cases of IgA Nephropathy in the 7MM
-
Total Treated Cases of IgA Nephropathy in the 7MM
Download the report to understand which factors are driving IgA Nephropathy epidemiology trends @ IgA Nephropathy Epidemiology Forecast
IgA Nephropathy Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the IgA Nephropathy market or expected to get launched during the study period. The analysis covers IgA Nephropathy market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the IgA Nephropathy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
IgA Nephropathy Therapies and Key Companies
-
Iptacopan (LNP023): Novartis
-
Atacicept: Vera Therapeutics
-
Atrasentan: Novartis
-
LNP023: Novartis
-
RC18: RemeGen Co., Ltd.
-
Telitacicept: RemeGen Co., Ltd.
-
Blisibimod: Anthera Pharmaceuticals
-
BION-1301: Chinook Therapeutics, Inc.
-
Fostamatinib: Rigel Pharmaceuticals
-
NEFECON: Calliditas Therapeutics AB
-
RO7434656: Hoffmann-La Roche
-
IONIS-FB-LRx: Ionis Pharmaceuticals
-
Tacrolimus: Keymed Biosciences
Discover more about therapies set to grab major IgA Nephropathy market share @ IgA Nephropathy Treatment Landscape
IgA Nephropathy Market Drivers
-
The recent launch of innovative drugs like TARPEYO and FILSPARI will fuel the market growth.
-
Based on the positive topline results from the interim analysis of pivotal Phase III ALIGN study of atrasentan in IgAN, Novartis plans to submit an application in 2024 for possible accelerated approval in the US. This is likelyto boost the IgA treatment landscape.
IgA Nephropathy Market Barriers
-
TARPEYO, can be used actively for an extended period i.e can also be used earlier in the disease progression to reduce proteinuria and protect the eGFR levels at an earlier stage. This support may require more extensive clinical experience and an updated label.
Scope of the IgA Nephropathy Market Report
-
Study Period: 2020–2034
-
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
-
Key IgA Nephropathy Companies: Novartis, Vera Therapeutics, RemeGen Co., Ltd., Anthera Pharmaceuticals, Chinook Therapeutics, Inc., Rigel Pharmaceuticals, Calliditas Therapeutics AB, Hoffmann-La Roche, Ionis Pharmaceuticals, Keymed Biosciences, and others
-
Key IgA Nephropathy Therapies: Iptacopan (LNP023), Atacicept, Atrasentan, RC18, Telitacicept, Blisibimod, BION-1301, Fostamatinib, NEFECON, RO7434656, IONIS-FB-LRx, Tacrolimus, and others
-
IgA Nephropathy Therapeutic Assessment: IgA Nephropathy current marketed and IgA Nephropathy emerging therapies
-
IgA Nephropathy Market Dynamics: IgA Nephropathy market drivers and IgA Nephropathy market barriers
-
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
-
IgA Nephropathy Unmet Needs, KOL’s views, Analyst’s views, IgA Nephropathy Market Access and Reimbursement
To know more about IgA Nephropathy companies working in the treatment market, visit @ IgA Nephropathy Clinical Trials and Therapeutic Assessment
Table of Contents
1. IgA Nephropathy Market Report Introduction
2. Executive Summary for IgA Nephropathy
3. SWOT analysis of IgA Nephropathy
4. IgA Nephropathy Patient Share (%) Overview at a Glance
5. IgA Nephropathy Market Overview at a Glance
6. IgA Nephropathy Disease Background and Overview
7. IgA Nephropathy Epidemiology and Patient Population
8. Country-Specific Patient Population of IgA Nephropathy
9. IgA Nephropathy Current Treatment and Medical Practices
10. IgA Nephropathy Unmet Needs
11. IgA Nephropathy Emerging Therapies
12. IgA Nephropathy Market Outlook
13. Country-Wise IgA Nephropathy Market Analysis (2020–2034)
14. IgA Nephropathy Market Access and Reimbursement of Therapies
15. IgA Nephropathy Market Drivers
16. IgA Nephropathy Market Barriers
17. IgA Nephropathy Appendix
18. IgA Nephropathy Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services